Edesa Biotech is trading $2.80, up 6.46%, with no fresh company announcement or reliable report clearly explaining the October 28 pre-market move. - FDA clearance for its Phase 2 vitiligo study was announced October 15; it is earlier context, not a confirmed new catalyst. - Broader index futures were modestly higher, but the move cannot be confidently attributed to the market. - Pre-market volume was not included in the supplied price context, so trading activity is unclear.